Quantum-Si Showcases Next-Generation Protein Sequencing Innovations at ASHG 2024 Annual Meeting

Quantum-Si Showcases Innovations at ASHG 2024 Annual Meeting

Quantum-Si Incorporated, recognized as The Protein Sequencing Company™, is set to make significant waves at the 2024 American Society of Human Genetics (ASHG) Annual Meeting. The company announces its participation in this pivotal event with a sponsored talk that highlights the transformative potential of Next-Generation Protein Sequencing (NGPS) in the field of genomics research. The presentation, titled “From Prediction to Protein: Validating Transcriptomics Data with Quantum-Si’s Next-Generation Protein Sequencing Technology,” features insights from Quantum-Si’s Head of Scientific Affairs, Dr. Meredith Carpenter, alongside Dr. Colette Felton from the University of California, Santa Cruz. Their collaborative discussion centers on the integration of transcriptomics and proteomics, a crucial area in understanding the complexities of biological systems.

Dr. Carpenter emphasizes the limitations often faced in genomic and transcriptomic data, which can fall short of representing the full spectrum of protein diversity. Quantum-Si’s NGPS technology addresses this gap by offering a high-resolution perspective that confirms the presence, abundance, and modifications of proteins. By validating RNA sequencing predictions at the protein level, this technology enhances the understanding of protein functions and their implications in various diseases. Dr. Felton plans to showcase advancements in long-read RNA sequencing aimed at identifying novel variants in cancer-related genes, further underscoring the importance of NGPS in validating these variants and elucidating their roles in disease pathology.

This strategic presentation at ASHG 2024 reflects Quantum-Si’s commitment to advancing multi-omics research and fostering collaborations that drive scientific innovation. CEO Jeff Hawkins reiterates the company's dedication to enhancing research capabilities, positioning Quantum-Si as a leader in the validation and analysis of protein data. Attendees at the conference can engage with Quantum-Si at booth #465, where they will learn more about the company’s cutting-edge technology and its diverse research applications in proteomics.

In addition to its presence at ASHG, Quantum-Si has announced an upcoming Investor & Analyst event scheduled for November 20, 2024, in New York City. This event will provide insights into the company's evolving technology roadmap and emerging applications in protein sequencing, underlining the expanding commercial opportunities their innovations present. Registration for the event is available for both in-person and virtual attendance, catering to a broad audience interested in Quantum-Si’s advancements in proteomics.

Quantum-Si continues to establish itself as a transformative force in the field of proteomics, utilizing its Platinum® instrument to push the boundaries of Next-Generation Protein Sequencing. The company's dedication to advancing scientific research and innovation positions it at the forefront of developments that are crucial for drug discovery and diagnostics.